Industry Academia Collaborations

Pneumococcal Conjugate Vaccine (PCV13)

Pneumococcal conjugate (PCV13) vaccine uses a carrier protein (CRM197) to provide biostable immunity in children below 2 years for pneumococcal disease. Biological E. Limited was able to make a vaccine that was new to the market using their in-house technology. CRM197 production is carried out in fermentation with optimized media using C. diphtheriae C7 strain, which was engineered in-house to increase CRM197 yield. The fermenter broth containing CRM197 is further processed by downstream processing. The purified CRM197 is analyzed to meet the predetermined quality attributes.

Area: Life Sciences & Biotechnology

Focused Area: Vaccine Immunology

Alignment with SDG: SDG 1, 3, 4, 5, 7 , 8, 9

Contact Info:

Paper Published: 80

Industry Name: M/s Biological E Limited

Industry Location: Hyderabad

Funding Agency: Technology Development Board (TDB)